Cost effectiveness of Gene Expression Profiling in Patients with Early-Stage Breast Cancer in a Middle-Income Country, Turkey: Results of a Prospective Multicenter Study


Ozmen V., ÇAKAR B., GÖKMEN E., Ozdogan M., Guler N., Uras C. , ...More

EUROPEAN JOURNAL OF BREAST HEALTH, vol.15, no.3, pp.183-190, 2019 (Journal Indexed in ESCI) identifier identifier

  • Publication Type: Article / Article
  • Volume: 15 Issue: 3
  • Publication Date: 2019
  • Doi Number: 10.5152/ejbh.2019.4761
  • Title of Journal : EUROPEAN JOURNAL OF BREAST HEALTH
  • Page Numbers: pp.183-190

Abstract

Objective: Breast cancer is a heterogenous disease, and genetic profiling helps to individualize adjuvant treatment. The Oncotype DX is a validated test to predict benefit of adjuvant systemic treatment. The aims of this study are to determine the costs of chemotherapy in government hospitals in Turkey and evaluate the cost-effectiveness of the Oncotype DX from the national insurance perspective.